{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:21:14Z","timestamp":1770794474357,"version":"3.50.0"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The achievement of the goals of the Immunization Agenda 2030 (IA2030) requires vaccines to be developed and implemented that meet the needs and requirements of the final users: vaccinators and vaccinees. A detailed and shared understanding of these needs should inform policy and programme guidance directing stakeholders\u2019 efforts and investments. Currently, relevant guidance documents only partially capture vaccine users\u2019 perspectives. Method: To help overcome this gap, we propose an operational research method grounded in the principles of the design approach that systematically maps and integrates user perspectives in vaccine development, policy, and implementation decisions. Results: The method, named the seven Ws, guides researchers through a three-step process. First, it clarifies the contribution of a vaccine to solving a public health problem\u2014the solution\u2013problem fit. Second, it maps potential implementation strategies for the vaccine in different settings. Lastly, it describes the relevant vaccine\u2019s use cases across the implementation strategies, elucidating the user requirements for the vaccine to be successfully implemented\u2014the solution\u2013provider and solution\u2013user fits. Conclusions: By explicitly pursuing these three fits, policymakers, vaccine developers, and programme managers will be able to better contribute towards the achievement of the IA2030 goals. This framework is intended as a conceptual contribution rather than an empirical validation study.<\/jats:p>","DOI":"10.3390\/vaccines13101075","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:17:35Z","timestamp":1761056255000},"page":"1075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improving the Suitability of Vaccine Design for Immunisation Programmes and Enhancing Vaccine Policy Quality Through User Research"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-1127","authenticated-orcid":false,"given":"Stefano","family":"Malvolti","sequence":"first","affiliation":[{"name":"MMGH Consulting GmbH, 8049 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6753-6518","authenticated-orcid":false,"given":"Melissa","family":"Malhame","sequence":"additional","affiliation":[{"name":"MMGH Consulting GmbH, 8049 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Soble","sequence":"additional","affiliation":[{"name":"MMGH Consulting GmbH, 8049 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1527-3065","authenticated-orcid":false,"given":"Carsten","family":"Mantel","sequence":"additional","affiliation":[{"name":"MMGH Consulting GmbH, 8049 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Ko","sequence":"additional","affiliation":[{"name":"MMGH Consulting GmbH, 8049 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Perrin","sequence":"additional","affiliation":[{"name":"Impact Hub, 8005 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Scarna","sequence":"additional","affiliation":[{"name":"Gavi, The Vaccine Alliance, 1218 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Menozzi-Arnaud","sequence":"additional","affiliation":[{"name":"Gavi, The Vaccine Alliance, 1218 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Amorij","sequence":"additional","affiliation":[{"name":"UNICEF Supply Division, 2150 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, May 20). IMMUNIZATION AGENDA 2030\u2014A Global Strategy to Leave no One Behind. Available online: https:\/\/www.immunizationagenda2030.org\/."},{"key":"ref_2","unstructured":"Wellcome Trust (2024, May 20). Effective Vaccine Ecosystem. Available online: https:\/\/wellcome.org\/reports\/effective-vaccine-ecosystem-equipped-meet-challenges-future-infectious-disease-threats."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"van Hoek, A.J., Ngama, M., Ismail, A., Chuma, J., Cheburet, S., Mutonga, D., Kamau, T., and Nokes, D.J. (2012). A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: Comparison between Rotarix and RotaTeq vaccines. PLoS ONE, 7.","DOI":"10.1371\/annotation\/6b9d910e-4c85-41ca-ae56-b5996e81820a"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/JCM.44.3.999-1017.2006","article-title":"Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002","volume":"44","author":"Beall","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.ijid.2009.05.010","article-title":"Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: Impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines","volume":"14","author":"Isaacman","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Perez Chacon, G., Estcourt, M.J., Totterdell, J., Marsh, J.A., Perrett, K.P., Campbell, D.E., Wood, N., Gold, M., Waddington, C.S., and Sullivan, M.O. (2024). Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial. PLoS Med., 21.","DOI":"10.1371\/journal.pmed.1004414"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2352909","DOI":"10.1080\/21645515.2024.2352909","article-title":"Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines","volume":"20","author":"Wanlapakorn","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1819","DOI":"10.1016\/S2214-109X(23)00421-7","article-title":"Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries","volume":"11","author":"Giersing","year":"2023","journal-title":"Lancet Glob. Health"},{"key":"ref_9","unstructured":"World Health Organization (2024, May 05). Preferred Product Characteristics and Target Product Profiles. Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/product-and-delivery-research\/ppcs."},{"key":"ref_10","unstructured":"Coalition for Epidemic Preparedness and Innovation (CEPI) (2024, May 04). COVID-19 Vaccines: Target Product Characteristics. Available online: https:\/\/media.tghn.org\/articles\/TPC_COVID-19_CEPI_Version_1.1_20200303.pdf."},{"key":"ref_11","unstructured":"Center for Biologics Evaluation and Research (CBER) (2024, May 04). Development and Licensure of Vaccines to Prevent COVID-19\u2014Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/139638\/download."},{"key":"ref_12","unstructured":"World Health Organization (2024, May 04). WHO Evidence Considerations for Vaccine Policy Development (ECVP). Available online: https:\/\/www.who.int\/publications\/m\/item\/who-evidence-considerations-for-vaccine-policy-development-%28ecvp%29#:~:text=WHO%E2%80%99s%20IVB%20department%20has%20developed%20a%20novel%20kind,to%20be%20required%20to%20support%20WHO%20policy%20recommendations."},{"key":"ref_13","unstructured":"World Health Organization (2024, March 04). WHO Evidence Considerations for Vaccine Policy Development for Tuberculosis Vaccines Intended for Adults and Adolescents. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/product-and-delivery-research\/who_evidence_considerations_vaccine_policy_development_tuberculosis_vaccines_intended_adults_adolescents.pdf?sfvrsn=4997b3f5_3."},{"key":"ref_14","unstructured":"World Health Organization (2024, March 03). Assessing the Programmatic Suitability of Vaccine Candidates for WHO Prequalification. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/148168\/WHO_IVB_14.10_eng.pdf?sequence=1."},{"key":"ref_15","unstructured":"World Health Organization (2013). Introduction of Pneumococcal Vaccine PCV10, Two Dose Presentation. A Handbook for District and Health Facility Staff, World Health Organization."},{"key":"ref_16","unstructured":"World Health Organization (2023). Global Research Agenda on Malaria Vaccine Introduction and Implementation: Research Brief, World Health Organization."},{"key":"ref_17","unstructured":"Leurs, B., and Roberts, I. (2024, May 20). What do We Mean by Design?. Available online: https:\/\/www.nesta.org.uk\/blog\/what-do-we-mean-by-design\/."},{"key":"ref_18","unstructured":"UNICEF (2024, May 20). Human-Centred Design\u2014Accelerating Results for Every Child by Design. Available online: https:\/\/www.readkong.com\/page\/human-centred-design-accelerating-results-for-every-child-6950610."},{"key":"ref_19","unstructured":"Ajayi, T., Obong\u2019o, C., Matemba, C., and Ali, D. (2024, March 03). Human-Centered Design and Behavioural Interventions to Improve Coverage\u2014TechNet Conference 2023. Available online: https:\/\/www.technet-21.org\/en\/resources\/presentation\/human-centered-design-and-behavioural-interventions-to-improve-coverage."},{"key":"ref_20","unstructured":"MMGH Consulting (2024, April 16). Method Paper: Defining Use Cases for Vaccines, Neglected Tropical Diseases and Diagnostics. Available online: https:\/\/www.mmglobalhealth.org\/methods\/use-case."},{"key":"ref_21","unstructured":"Ivar Jacobson International (2011). USE-CASE 2.0\u2014The Guide to Succeeding with Use Cases, Ivar Jacobson International."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Malvolti, S., Malhame, M., Mantel, C.F., Le Rutte, E.A., and Kaye, P.M. (2021). Human leishmaniasis vaccines: Use cases, target population and potential global demand. PLoS Negl. Trop. Dis., 15.","DOI":"10.1101\/2021.07.09.21260268"},{"key":"ref_23","unstructured":"Wellcome Trust (2024). Conducting Market Analyses for New Tuberculosis Vaccines for Adolescents and Adults: A Summary of One Approach Applied to M72\/AS01E, Wellcome Trust."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","article-title":"Effectiveness-implementation hybrid designs: Combining elements of clinical effectiveness and implementation research to enhance public health impact","volume":"50","author":"Curran","year":"2012","journal-title":"Med. Care"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Malvolti, S., Ko, M., Menozzi-Arnaud, M., Mantel, C., Jarrahian, C., Amorij, J.-P., Giersing, B., and Hasso-Agopsowicz, M. (2023). Exploring potential applications of measles and rubella microarray patches (MR-MAPs): Use case identification. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1165110"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00004703-200512000-00009","article-title":"Parental beliefs and decision making about child and adolescent immunization: From polio to sexually transmitted infections","volume":"26","author":"Sturm","year":"2005","journal-title":"J. Dev. Behav. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.vaccine.2023.12.047","article-title":"A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches","volume":"42","author":"Soble","year":"2024","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"127233","DOI":"10.1016\/j.vaccine.2025.127233","article-title":"Identification and sizing of the current use cases for seasonal influenza vaccines","volume":"60","author":"Soble","year":"2025","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"George, G., Strauss, M., Lansdell, E., Nadesan-Reddy, N., Moroe, N., Reddy, T., Eshun-Wilsonova, I., and Moshabela, M. (2022). South African University Staff and Students\u2019 Perspectives, Preferences, and Drivers of Hesitancy Regarding COVID-19 Vaccines: A Multi-Methods Study. Vaccines, 10.","DOI":"10.3390\/vaccines10081250"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/INF.0000000000000236","article-title":"Parental views on childhood influenza vaccination","volume":"33","author":"Thors","year":"2014","journal-title":"Pediatr. Infect. Dis. J."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:46:46Z","timestamp":1761058006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["vaccines13101075"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13101075","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}